|
1
|
Harris NL, Jaffe ES, Stein H, Banks PM,
Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter
KC, et al: A revised European-American classification of lymphoid
neoplasms: A proposal from the International Lymphoma Study Group.
Blood. 84:1361–1392. 1994.PubMed/NCBI
|
|
2
|
Maxwell SA and Mousavi-Fard S:
Non-Hodgkins B-cell lymphoma: Advances in molecular strategies
targeting drug resistance. Exp Biol Med (Maywood). 238:971–990.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shankland KR, Armitage JO and Hancock BW:
Non-Hodgkin lymphoma. Lancet. 380:848–857. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yagi K, Yamamoto K, Umeda S, Abe S, Suzuki
S, Onishi I, Kirimura S, Fukayama M, Arai A, Kitagawa M, et al:
Expression of multidrug resistance 1 gene in B-cell lymphomas:
Association with follicular dendritic cells. Histopathology.
62:414–420. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lwin T, Hazlehurst LA, Dessureault S, Lai
R, Bai W, Sotomayor E, Moscinski LC, Dalton WS and Tao J: Cell
adhesion induces p27Kip1-associated cell-cycle arrest
through down-regulation of the SCFSkp2 ubiquitin ligase
pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.
Blood. 110:1631–1638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lwin T, Zhao X, Cheng F, Zhang X, Huang A,
Shah B, Zhang Y, Moscinski LC, Choi YS, Kozikowski AP, et al: A
microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop
in non-Hodgkin B cell lymphomas. J Clin Invest. 123:4612–4626.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mraz M, Zent CS, Church AK, Jelinek DF, Wu
X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, et al:
Bone marrow stromal cells protect lymphoma B-cells from
rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4)
with natalizumab can overcome this resistance. Br J Haematol.
155:53–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nie J, Liu L, He F, Fu X, Han W and Zhang
L: CKIP-1: A scaffold protein and potential therapeutic target
integrating multiple signaling pathways and physiological
functions. Ageing Res Rev. 12:276–281. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang L, Xing G, Tie Y, Tang Y, Tian C, Li
L, Sun L, Wei H, Zhu Y and He F: Role for the pleckstrin homology
domain-containing protein CKIP-1 in AP-1 regulation and apoptosis.
EMBO J. 24:766–778. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tokuda E, Fujita N, Oh-hara T, Sato S,
Kurata A, Katayama R, Itoh T, Takenawa T, Miyazono K and Tsuruo T:
Casein kinase 2-interacting protein-1, a novel Akt pleckstrin
homology domain-interacting protein, down-regulates PI3K/Akt
signaling and suppresses tumor growth in vivo. Cancer Res.
67:9666–9676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nie J, Liu L, Xing G, Zhang M, Wei R, Guo
M, Li X, Xie P, Li L, He F, et al: CKIP-1 acts as a colonic tumor
suppressor by repressing oncogenic Smurf1 synthesis and promoting
Smurf1 autodegradation. Oncogene. 33:3677–3687. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vilk G, Saulnier RB, St Pierre R and
Litchfield DW: Inducible expression of protein kinase CK2 in
mammalian cells. Evidence for functional specialization of CK2
isoforms. J Biol Chem. 274:14406–14414. 1999.
|
|
13
|
Zhang L, Wang Y, Xiao F, Wang S, Xing G,
Li Y, Yin X, Lu K, Wei R, Fan J, et al: CKIP-1 regulates macrophage
proliferation by inhibiting TRAF6-mediated Akt activation. Cell
Res. 24:742–761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang Y, Liu F, Mao F, Hang Q, Huang X, He
S, Wang Y, Cheng C, Wang H, Xu G, et al: Interaction with cyclin
H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal
binding protein 2 (CtBP2) and promotes cancer cell migration. J
Biol Chem. 288:9028–9034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Tie Y, Tian C, Xing G, Song Y,
Zhu Y, Sun Z and He F: CKIP-1 recruits nuclear ATM partially to the
plasma membrane through interaction with ATM. Cell Signal.
18:1386–1395. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Canton DA, Olsten ME, Niederstrasser H,
Cooper JA and Litchfield DW: The role of CKIP-1 in cell morphology
depends on its interaction with actin-capping protein. J Biol Chem.
281:36347–36359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hennessy BT, Smith DL, Ram PT, Lu Y and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu T, Fang Y, Zhang H, Deng M, Gao B, Niu
N, Yu J, Lee S, Kim J, Qin B, et al: HEATR1 negatively regulates
Akt to help sensitize pancreatic cancer cells to chemotherapy.
Cancer Res. 76:572–581. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perna D, Karreth FA, Rust AG,
Perez-Mancera PA, Rashid M, Iorio F, Alifrangis C, Arends MJ,
Bosenberg MW, Bollag G, et al: BRAF inhibitor resistance mediated
by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc
Natl Acad Sci USA. 112:E536–E545. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hazlehurst LA, Damiano JS, Buyuksal I,
Pledger WJ and Dalton WS: Adhesion to fibronectin via β1 integrins
regulates p27kip1 levels and contributes to cell
adhesion mediated drug resistance (CAM-DR). Oncogene. 19:4319–4327.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lwin T, Hazlehurst LA, Li Z, Dessureault
S, Sotomayor E, Moscinski LC, Dalton WS and Tao J: Bone marrow
stromal cells prevent apoptosis of lymphoma cells by upregulation
of anti-apoptotic proteins associated with activation of NF-kappaB
(RelB/p52) in non-Hodgkins lymphoma cells. Leukemia. 21:1521–1531.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang L, Tang Y, Tie Y, Tian C, Wang J,
Dong Y, Sun Z and He F: The PH domain containing protein CKIP-1
binds to IFP35 and Nmi and is involved in cytokine signaling. Cell
Signal. 19:932–944. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li ZW and Dalton WS: Tumor
microenvironment and drug resistance in hematologic malignancies.
Blood Rev. 20:333–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang K, Jiang Y, Zheng W, Liu Z, Li H, Lou
J, Gu M and Wang X: Silencing of human
phosphatidylethanolamine-binding protein 4 enhances
rituximab-induced death and chemosensitization in B-cell lymphoma.
PLoS One. 8:e568292013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakagawa Y, Nakayama H, Nagata M, Yoshida
R, Kawahara K, Hirosue A, Tanaka T, Yuno A, Matsuoka Y, Kojima T,
et al: Overexpression of fibronectin confers cell adhesion-mediated
drug resistance (CAM-DR) against 5-FU in oral squamous cell
carcinoma cells. Int J Oncol. 44:1376–1384. 2014.PubMed/NCBI
|
|
26
|
Bai H, Li H, Li W, Gui T, Yang J, Cao D
and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of
distinct invasive and migratory capacities in human ovarian cancer
cell lines. Oncotarget. 6:25520–25532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G
and Zhang Q: RY-2f, an isoflavone analog, overcomes cisplatin
resistance to inhibit ovarian tumorigenesis via targeting the
PI3K/AKT/mTOR signaling pathway. Oncotarget. 6:25281–25294. 2015.
View Article : Google Scholar : PubMed/NCBI
|
